Manschot W A, Van Strik R
Br J Ophthalmol. 1987 May;71(5):348-52. doi: 10.1136/bjo.71.5.348.
Analysis of the literature shows that dissemination of choroidal melanomas generally occurs after the 7 mm diameter stage, that doubling times of uveal melanomas vary from 30 to 365 days, and that death from metastases occurs 30-40 doubling times after dissemination. Tumour related death within three years after therapy is caused by pre-existing metastases. Survival rates for less than four years after therapy are therefore irrelevant in evaluating the efficacy of therapeutic regimens. Considerably higher postirradiation than postenucleation death rates after a mean 10-year follow-up period have been reported, and this difference can be explained by a reported mean clinical tumour regression rate of 31% two years after irradiation and histopathological studies which revealed that 42 out of 43 irradiated melanomas contained viable tumour, while only 50% showed necrosis. The doubtful value of preserving vision does not justify the high risk of avoidable death from metastases in irradiated patients.
文献分析表明,脉络膜黑色素瘤通常在直径达到7毫米阶段后发生扩散,葡萄膜黑色素瘤的倍增时间在30至365天之间,转移导致的死亡发生在扩散后的30 - 40个倍增时间之后。治疗后三年内的肿瘤相关死亡是由先前存在的转移灶引起的。因此,治疗后不到四年的生存率在评估治疗方案的疗效时并无关联。据报道,平均10年随访期后,放疗后的死亡率显著高于眼球摘除术后的死亡率,这种差异可以通过放疗后两年报告的平均临床肿瘤消退率为31%以及组织病理学研究来解释,该研究显示43例接受放疗的黑色素瘤中有42例含有存活肿瘤,而只有50%显示坏死。保留视力的可疑价值并不能证明放疗患者因转移而面临的可避免死亡的高风险是合理的。